ClinicalTrials.gg
CompletedNCT01034995AGATEUpdated Apr 14, 2011

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder

A Phase 2 interventional study of SSR125543 and escitalopram in Major Depression, sponsored by Sanofi. Completed at 73 sites in 12 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2011-04-14.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Depressive Disorder, Major by Sanofi — none open to participants now, none under way, none of them phase 3. Depressive Disorder, Major · Sanofi.

Planned enrollment
5th of 14
580 · median 519
Started
2010
the only one that year
Phase 2
3 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Depressive Disorder, Major by Sanofi, this one is the 5th largest by planned enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 13th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies in Depressive Disorder, Major by Sanofi is open now. The open studies under Depressive Disorder, Major, anywhere →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Depressive Disorder, Major by Sanofi as a file.
02

Study summary

Primary Objective:

  • To evaluate the efficacy of three fixed doses of SSR125543 (20 mg daily, 50 mg daily, and 100 mg daily) compared to placebo in outpatients with major depressive disorder, as assessed by the change from baseline (Day -1) to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score.

Secondary Objectives:

  • To evaluate the tolerability and safety of SSR125543 in outpatients with major depressive disorder
  • To evaluate plasma concentrations of SSR125543
Read the detailed description

This duration of this trial is 11 weeks.

03

Conditions studied

  • Major Depression
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of major depressive disorder, as defined by the , 4th edition, Text Revision (DSM-IV-TR) criteria (296.3) and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI).

Exclusion criteria

Exclusion criteria:

  • Inpatient hospitalization at screening
  • Symptoms of depression present for \<30 days or >2 years
  • Significant suicide risk
  • Mild depression as measured by standard clinical research scales
  • History of failure to respond to antidepressant treatment
  • Other psychiatric conditions that could obscure the results of the study
  • For women of , the unwillingness to use highly effective means of

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
580 participants (estimated)

Study arms

  • Experimental
    SSR125543 20 mg

    1 capsule of SSR125543 20 mg + 1 capsule of placebo

    Drug: SSR125543

  • Experimental
    SSR125543 50 mg

    1 capsule of SSR125543 50 mg + 1 capsule of placebo

    Drug: SSR125543

  • Experimental
    SSR125543 100 mg

    2 capsules of SSR125543 50 mg

    Drug: SSR125543

  • Active comparator
    escitalopram 10 mg

    1 capsule of escitalopram 10 mg + 1 capsule of placebo

    Drug: escitalopram

  • Placebo comparator
    placebo

    2 capsules of placebo

    Drug: placebo

Interventions

  • Pharmaceutical form: capsule Route of administration: oral

  • Pharmaceutical form: encapsulated tablets Route of administration: oral

  • Drugplacebo

    Pharmaceutical form: capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change from baseline (Day -1) to Day 56 in the 17-item HAM-D total score

    Time frame: 8 weeks

Secondary outcomes

  1. Change from baseline in HAM-D depressed mood item

    Time frame: 8 weeks

  2. Change from baseline in HAM-D responders (50% improvement)

    Time frame: 8 weeks

  3. Changes from baseline in the HAM-D core and factor scores

    Time frame: 8 weeks

  4. Changes from baseline in the Montgomery-Asberg depression rating scale (MADRS) total score

    Time frame: 8 weeks

  5. Changes from baseline in the Clinical Global Impression (CGI) Severity of Illness score

    Time frame: 8 weeks

07

Study locations

73 sites
  • Sanofi-Aventis Investigational Site Number 056002
    Asse, 1730, Belgium
  • Sanofi-Aventis Investigational Site Number 056003
    Bruxelles, 1180, Belgium
  • Sanofi-Aventis Investigational Site Number 056001
    Liège, 4000, Belgium
  • Sanofi-Aventis Investigational Site Number 124011
    Burlington, L7R 4E2, Canada
  • Sanofi-Aventis Investigational Site Number 124012
    Chatham, N7M 1B7, Canada
  • Sanofi-Aventis Investigational Site Number 124004
    Edmonton, T6L 5X8, Canada
  • Sanofi-Aventis Investigational Site Number 124003
    Gatineau, J9A 1K7, Canada
  • Sanofi-Aventis Investigational Site Number 124001
    Kelowna, V1Y 1Z9, Canada
  • Sanofi-Aventis Investigational Site Number 124006
    Mississauga, L5M 4N4, Canada
  • Sanofi-Aventis Investigational Site Number 124008
    Penticton, V2A 4M4, Canada
  • Sanofi-Aventis Investigational Site Number 124007
    Sherbrooke, J1V 4J7, Canada
  • Sanofi-Aventis Investigational Site Number 124009
    Toronto, M3H 5S4, Canada
  • Sanofi-Aventis Investigational Site Number 152001
    Santiago, 750-0710, Chile
  • Sanofi-Aventis Investigational Site Number 152002
    Santiago, 751-0041, Chile
  • Sanofi-Aventis Investigational Site Number 152003
    Santiago, 756-0356, Chile
  • Sanofi-Aventis Investigational Site Number 152005
    Santiago, 8053095, Chile
  • Sanofi-Aventis Investigational Site Number 152006
    Santiago, 890-0085, Chile
  • Sanofi-Aventis Investigational Site Number 152004
    Santiago, Chile
  • Sanofi-Aventis Investigational Site Number 152007
    Valparaiso, 236-0002, Chile
  • Sanofi-Aventis Investigational Site Number 152008
    Vina Del Mar, Chile
  • Sanofi-Aventis Investigational Site Number 233001
    Tallinn, 10613, Estonia
  • Sanofi-Aventis Investigational Site Number 233002
    Tallinn, 11911, Estonia
  • Sanofi-Aventis Investigational Site Number 233004
    Tallinn, 13419, Estonia
  • Sanofi-Aventis Investigational Site Number 233003
    Tartu, 50406, Estonia
  • Sanofi-Aventis Investigational Site Number 246001
    Helsinki, 00260, Finland
  • Sanofi-Aventis Investigational Site Number 246003
    Helsinki, 00530, Finland
  • Sanofi-Aventis Investigational Site Number 246005
    Järvenpää, 04400, Finland
  • Sanofi-Aventis Investigational Site Number 246002
    Tampere, 33200, Finland
  • Sanofi-Aventis Investigational Site Number 246004
    Turku, 20100, Finland
  • Sanofi-Aventis Investigational Site Number 250008
    Arcachon, 33120, France
  • Sanofi-Aventis Investigational Site Number 250007
    Dole, 39100, France
  • Sanofi-Aventis Investigational Site Number 250006
    Elancourt, 78990, France
  • Sanofi-Aventis Investigational Site Number 250001
    Grenoble, 38043, France
  • Sanofi-Aventis Investigational Site Number 250003
    Montpellier Cedex 05, 34295, France
  • Sanofi-Aventis Investigational Site Number 250005
    Nimes Cedex 9, 30029, France
  • Sanofi-Aventis Investigational Site Number 250004
    Orvault, 44700, France
  • Sanofi-Aventis Investigational Site Number 250002
    Toulouse, 31000, France
  • Sanofi-Aventis Investigational Site Number 276008
    Achim, 28832, Germany
  • Sanofi-Aventis Investigational Site Number 276002
    Berlin, 10629, Germany
  • Sanofi-Aventis Investigational Site Number 276004
    Dresden, 01307, Germany
  • Sanofi-Aventis Investigational Site Number 276005
    Leipzig, 04107, Germany
  • Sanofi-Aventis Investigational Site Number 276006
    Mannheim, 68159, Germany
  • Sanofi-Aventis Investigational Site Number 276007
    München, 80333, Germany
  • Sanofi-Aventis Investigational Site Number 276001
    Schwerin, 19053, Germany
  • Sanofi-Aventis Investigational Site Number 276003
    Würzburg, 97070, Germany
  • Sanofi-Aventis Investigational Site Number 528001
    Den Haag, 2512 VA, Netherlands
  • Sanofi-Aventis Investigational Site Number 643006
    Moscow, 117152, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643005
    Nizhny Novgorod, 603155, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643008
    Rostov-Na-Donu, 344010, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643010
    Saint-Petersburg, 190121, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643004
    Samara, 443016, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643007
    Smolensk, 214019, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643009
    St-Petersburg, 190121, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643011
    St-Petersburg, 191119, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643003
    St-Petersburg, 192019, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643002
    St-Petersburg, 194044, Russian Federation
  • Sanofi-Aventis Investigational Site Number 643001
    St.-Petersburg, 190005, Russian Federation
  • Sanofi-Aventis Investigational Site Number 703101
    Bratislava 2, 82606, Slovakia
  • Sanofi-Aventis Investigational Site Number 703102
    Bratislava, 81107, Slovakia
  • Sanofi-Aventis Investigational Site Number 703104
    Michalovce, 07101, Slovakia
  • Sanofi-Aventis Investigational Site Number 703105
    Rimavska Sobota, 979 12, Slovakia
  • Sanofi-Aventis Investigational Site Number 703103
    Roznava, 04801, Slovakia
  • Sanofi-Aventis Investigational Site Number 710005
    Cape Town, 7530, South Africa
  • Sanofi-Aventis Investigational Site Number 710001
    Cape Town, 7646, South Africa
  • Sanofi-Aventis Investigational Site Number 710006
    Centurion, 0157, South Africa
  • Sanofi-Aventis Investigational Site Number 710002
    Durban, 3629, South Africa
  • Sanofi-Aventis Investigational Site Number 710003
    Pretoria, 0181, South Africa
  • Sanofi-Aventis Investigational Site Number 710004
    Somerset West, 7130, South Africa
  • Sanofi-Aventis Investigational Site Number 752004
    Linköping, 582 16, Sweden
  • Sanofi-Aventis Investigational Site Number 752002
    Lund, 223 61, Sweden
  • Sanofi-Aventis Investigational Site Number 752003
    Malmö, 211 52, Sweden
  • Sanofi-Aventis Investigational Site Number 752005
    Stockholm, 112 34, Sweden
  • Sanofi-Aventis Investigational Site Number 752001
    Uppsala, 753 10, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2009
First posted
Dec 18, 2009
Start
Feb 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Last update
Apr 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01034995
Lead sponsor
Sanofi
First posted
Dec 18, 2009
Start date
Feb 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Apr 14, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crinecerfont

Start the discussion